"However, there are logistical challenges as the vaccine has to be kept in ultra-cold storage at below minus 80C."

Does anyone know how many of the other vaccine candidates have this limitation? It seems to me that a vaccine with easier logistics might still end up having a bigger impact overall, despite not being the first - although that of course needs to be combined with the ease of production too (I don't know how easy it is to mass produce these new RNA vaccines compared to more traditional ones).